Skip to content

An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief

An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05845970
Enrollment
100
Registered
2023-05-06
Start date
2023-02-08
Completion date
2023-07-01
Last updated
2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menstrual Pain, Premenstrual Syndrome

Brief summary

Women often experience significant pain during their periods which can significantly impact on quality of life. In this study, two products that are used to alleviate period pain will be examined. One test product is botanically based, and the other is a traditional over-the-counter pain reliever with additional components added to support less painful periods. The trial will be a cross-over trial where participants will use the botanical product before, during, and after their first period. Participants will use the botanical product alongside a traditional over-the-counter period product during their second period. Participants will answer surveys and have blood drawn at a third-party lab to answer the main objectives of this trial.

Interventions

OTHERPamprin Botanicals

Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.

COMBINATION_PRODUCTPamprin Botanicals + Pamprin Menstrual Pain Relief

Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).

Sponsors

Citruslabs
CollaboratorINDUSTRY
Focus Consumer Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Female between 18-40 years of age. * Must be in good health with no significant chronic conditions and a BMI under 35. * Must experience period pain and other PMS symptoms. * Must have a regular menstrual cycle with a bleed week. * If using hormonal contraception, must do so for at least three months * If using oral contraception, must allow for bleed week. * Must be able to predict their bleed week. * Willing to abstain from strenuous exercise 24 hours before each of the three blood draws in this trial.

Exclusion criteria

* Suffers from pre-existing conditions that would prevent them from adhering to the protocol. * Anyone with known severe allergic reactions. * Anyone with a previous negative experience with acetaminophen. * Unwilling to follow the study protocol. * Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study. * Anyone who uses other supplements for period pain and PMS symptoms. * Current use of an extended activity hormonal contraception (examples include Depo-provera or Nexplanon.

Design outcomes

Primary

MeasureTime frameDescription
Changes in common menstrual cycle symptoms [Time Frame: 2 menstrual cycles (approximately 60 days)]60 daysMenstrual cycle symptoms will be measured via study-specific questionnaires.

Secondary

MeasureTime frameDescription
Changes in blood biomarkers during the menstrual cycle [Time Frame: 2 menstrual cycles (approximately 60 days)]60 dayshs-CRP and cortisol will be measured via blood draws. Blood draws will occur at Baseline, Day 5 of bleeding during their first menstrual cycle during the study, and Day 5 of bleeding during their second menstrual cycle during the study.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026